Continuing Education Activity

Pediatric bronchiolitis is an acute lower respiratory tract infection primarily caused by viral pathogens. This condition is one of the most common illnesses in infants and children aged 2 or younger and is thus one of the leading causes of hospitalization in this age group, particularly during the winter months. The illness typically begins with a few days of upper respiratory symptoms, such as nasal congestion and rhinorrhea, which progress to lower respiratory symptoms, including wheezing, cough, and feeding difficulties, especially in young infants who rely on nasal breathing. In severe cases, bronchiolitis can cause respiratory distress, hypoxemia, and dehydration, often requiring urgent care or hospitalization for supportive treatment. Respiratory syncytial virus (RSV) is the most common cause, and recent advancements in RSV vaccination are expected to help reduce the global burden of bronchiolitis.

Management is largely supportive, focusing on hydration, airway suctioning, and monitoring for respiratory failure. In severe cases, supplemental oxygen and mechanical ventilation may be necessary. Recent advancements in RSV vaccination are expected to reduce bronchiolitis cases and related complications. This activity reviews bronchiolitis, emphasizing its pathophysiology, clinical presentation, and evidence-based management strategies. This activity also highlights the critical role of the interprofessional healthcare team in optimizing outcomes for infants and children with bronchiolitis while providing insights into the latest advancements in prevention, including RSV vaccines. This activity also enables healthcare professionals to gain the skills to assess, treat, and educate families about the condition, ultimately enhancing patient care and reducing disease-related complications.

Objectives:

• Identify the clinical features and common viral pathogens responsible for pediatric bronchiolitis.
• Implement evidence-based supportive care measures, including hydration, airway suctioning, and oxygen therapy, for hospitalized patients.
• Apply updated guidelines for the prevention of bronchiolitis, including respiratory syncytial virus vaccines and monoclonal antibody therapies.
• Collaborate with an interprofessional healthcare team to manage severe bronchiolitis and ensure high-risk infants receive timely preventive measures and follow-up care.

Introduction

Pediatric bronchiolitis is a lower respiratory tract infection primarily caused by viral pathogens. This condition is among the most common illnesses in children aged 2 or younger and the leading cause of hospitalization in this age group.

Bronchiolitis is primarily a clinical diagnosis, but viral testing may be necessary in severe cases requiring hospitalization. Identifying the specific viral cause can support infection control measures and prevent nosocomial spread. While most hospitalized infants have identifiable risk factors that increase their susceptibility, otherwise healthy infants and older children can also develop severe infections that necessitate hospitalization. In severe cases, infants with significant respiratory compromise may require mechanical ventilation.

Respiratory syncytial virus (RSV) is the primary cause of bronchiolitis, although nearly all respiratory viruses can cause the condition in infants and young children. RSV bronchiolitis significantly contributes to the global disease burden, with approximately 33 million cases annually, 95% of which occur in low-income countries. Recent estimates indicate that around 3.6 million infants are hospitalized for bronchiolitis each year, with up to 118,000 deaths attributed to the condition or related complications. Unfortunately, half of these deaths occur within the first 6 months of life, and 97% of all infant deaths from bronchiolitis are reported in low- and middle-income countries.[1]

Etiology

RSV is the leading infectious agent in acute bronchiolitis among children, accounting for up to two-thirds of cases. Human metapneumovirus and parainfluenza virus type 3 contribute to nearly half of the remaining cases.

During the COVID-19 pandemic, a small number of SARS-CoV-2–related bronchiolitis cases were reported, alongside a significant decline in RSV bronchiolitis admissions. However, this trend reversed after the pandemic, with RSV again emerging as the predominant cause of bronchiolitis.[2] 

Although RSV is the leading pathogen causing bronchiolitis, other respiratory viruses can also contribute, albeit less frequently. These include adenoviruses, bocaviruses, coronaviruses (such as SARS-CoV-2), enteroviruses, human metapneumovirus, influenza, measles, and rhinoviruses.[3][4] Occasionally, Mycoplasma pneumoniae has been associated with a bronchiolitis-like illness characterized by wheezing.

With the expansion of therapeutic options for respiratory infections, identifying the specific causative agent has become increasingly important. This is particularly vital in critically ill children, as determining the cause can guide targeted treatments and enhance outcomes.

Epidemiology

Bronchiolitis is one of the most common respiratory illnesses affecting infants and young children worldwide, referring to a clinical condition predominantly seen in this age group.[1] This condition is characterized by wheezing, tachypnea, and other common symptoms of viral respiratory tract infections, such as cough, nasal congestion, and rhinorrhea. The condition most often occurs in children between 2 and 6 months of age.

The severity of bronchiolitis varies significantly, from mild wheezing with an increased respiratory rate (commonly referred to as the "happy wheezer") to severe respiratory distress that may progress to respiratory failure, necessitating intubation and mechanical ventilation. Early recognition and timely management are essential to prevent complications and improve outcomes in severe cases.

Bronchiolitis outbreaks occur annually, typically during the fall and winter months in temperate climates, aligning with the circulation of other respiratory viruses. In subtropical and tropical regions, bronchiolitis can occur year-round, with outbreaks more common during the rainy season. In desert climates, cases are usually confined to a narrow window in winter, with minimal or no activity reported throughout the rest of the year.[1][5] Factors such as temperature, humidity, and UV-B radiation are believed to influence the seasonality of the virus. However, further research is needed to better understand the factors driving these patterns worldwide.[5]

Many respiratory viruses have relatively short incubation periods, typically lasting 2 to 3 days. In older children and adults, viral shedding is generally brief, lasting only a few days. However, viral shedding can persist for more than 4 weeks in infants, young children, and immunocompromised individuals.[6] This prolonged viral shedding can complicate infection control efforts and challenge the interpretation of PCR diagnostics. Residual shedding from a recent but inactive infection may be detected, potentially confounding the diagnosis of a new illness.

Various host, environmental, and social factors contribute to an increased risk of severe bronchiolitis in infants and children (see Table below).[7][8][9][10] Recognizing these risk factors is essential for guiding prevention strategies and implementing early interventions to mitigate the severity of the illness.

Table

Table. Risk Factors for Severe Bronchiolitis.

Pathophysiology

Most viral pathogens enter the body through the nasopharynx and oral or conjunctival mucosal surfaces. RSV, the most common cause of bronchiolitis, initially replicates in the nasopharynx before spreading to respiratory tract cells lining the terminal bronchioles. RSV primarily infects type I alveolar pneumocytes, with some involvement of type II alveolar pneumocytes, while sparing basal cells. Aspiration of upper respiratory tract secretions and subsequent cell-to-cell spread typically leads to lower respiratory tract involvement within 1 to 3 days of the initial upper respiratory infection.

Infection of the respiratory tract cells lining the terminal bronchioles leads to cellular damage and activates local inflammatory responses. The virus-induced inflammation triggers the release of cytokines and chemokines, resulting in edema, increased mucus production, and the recruitment of additional inflammatory cells to the respiratory tract.[11] 

Dead bronchial epithelial and inflammatory cells slough into the inflamed, mucus-filled airways, further exacerbating small airway obstruction. Infants are particularly prone to airway obstruction due to the small caliber of their airways, which can result in wheezing and air trapping. Atelectasis of the lung parenchyma and resulting hypoxemia further contribute to varying levels of respiratory distress.

The pathology of bronchiolitis involves necrosis of airway epithelial cells, along with proliferation of the bronchiolar epithelium and cellular infiltration of monocytes and T cells affecting both bronchial and pulmonary arterioles. Neutrophilic infiltration can also be observed between the vascular structures and small airways.[12][13] Airway obstruction and air trapping result in increased airway resistance. Additionally, neutrophilia is frequently observed in pediatric cases following bronchoalveolar lavage.[14]

History and Physical

The history and physical examination of infants with bronchiolitis typically reveal a consistent clinical presentation. During the initial days, symptoms include cough, congestion, and rhinorrhea, with or without fever, as viral replication occurs in the upper respiratory tract.

Parents often describe initial cold-like symptoms, which progress to signs such as "breathing funny" or "breathing fast," difficulty feeding, or bluish discoloration of the lips and nailbeds. They may also observe nasal flaring and intercostal retractions as the infant struggles to optimize air entry.

On physical examination, vital signs may show a low-grade fever, increased respiratory rate, and hypoxemia. Respiratory rates exceeding 100 breaths per minute are common and often contribute to feeding difficulties in infants.

Pulse oximetry typically shows varying degrees of hypoxemia due to mucous plugging and atelectasis, resulting in a ventilation-perfusion mismatch.[15] Cyanosis of the lips and nail beds may also be observed. Key physical findings include grunting, nasal flaring, intercostal retractions, and belly breathing. Diffuse inspiratory and expiratory wheezes across all lung fields are characteristic of viral bronchiolitis. A tired, pale-appearing infant with poor air entry is a concerning sign of impending respiratory collapse, requiring urgent intubation and ventilation.

Evaluation

Bronchiolitis is primarily diagnosed clinically. Diagnosis and assessment of illness severity should be based on a comprehensive history of the present illness and the patient's clinical signs. Oxygen saturation levels can help determine the need for supplemental oxygen and hospitalization. An important clinical indicator of the severity of an infant's illness is their ability to breastfeed or bottle-feed. Observing feeding behavior is crucial; if the infant experiences coughing, difficulty breathing, or sputtering during feeding, hospitalization for intravenous fluids should be considered.

Infants with tachypnea exceeding 60 breaths per minute or oxygen saturation levels below 92% should be considered for hospitalization and supplemental oxygen. Patients with severe respiratory compromise may benefit from a trial of aerosolized albuterol.[16] In cases of clinical fatigue or severe hypoxemia, endotracheal intubation and mechanical ventilation should be strongly considered.

Laboratory investigations for patients with bronchiolitis should include viral identification when possible. Rapid diagnostic assays, such as nucleic acid amplification testing, immunofluorescence, and enzyme immunoassay techniques, are commercially available to detect viral RNA or antigens in nasopharyngeal or other respiratory specimens. These results can help clinicians tailor the patient's workup and management. In addition to guiding treatment, this information is crucial for decisions regarding room placement, isolation, and grouping of hospitalized patients. Chest x-rays are generally not recommended, as they often show nonspecific findings such as lung hyperinflation, interstitial markings, and peribronchial thickening, which are typically not diagnostic.

Treatment / Management

The management of bronchiolitis is primarily supportive, and it usually focuses on ensuring hydration, performing upper airway suctioning as needed, and monitoring for signs of respiratory failure or the need for intubation and mechanical ventilation. Infants with oxygen saturation levels below 92% in room air should receive supplemental oxygen, and continuous pulse oximetry monitoring is recommended for hospitalized patients.

Antipyretics should be administered if a fever develops. Although bronchodilators are not universally effective, a trial of aerosolized albuterol may be considered, especially for infants with severe respiratory compromise.[16] Glucocorticoids and racemic epinephrine have not shown efficacy and are not recommended. Antibiotics should be reserved for cases with clear evidence of a superimposed infection in addition to bronchiolitis.

If an infant tests positive for influenza, oseltamivir (Tamiflu™) is recommended, particularly if administered within the first 48 hours of symptom onset. Early initiation of this antiviral improves its effectiveness and may positively impact the course of the illness. Similarly, if SARS-CoV-2 is identified, treatment with nirmatrelvir-ritonavir (Paxlovid™) can be considered. Prevention is preferred over treatment, and new tools are now available to help prevent bronchiolitis. Palivizumab (Synagis™)—a monoclonal antibody targeting the F protein of RSV—was previously recommended for high-risk infants during their first year. This product was administered monthly via intramuscular injection during RSV season but was unavailable for otherwise healthy infants in their first 3 months of life—a group that experiences a substantial burden of RSV disease cases.

Fortunately, 2 options are now available for RSV prevention—vaccination of pregnant individuals with an RSV vaccine (Abrysvo™) or administering the newer monoclonal antibody nirsevimab (Beyfortus™) to infants during their first RSV season if the birth parent did not receive an RSV vaccine.[17] The availability of these products may vary, so clinicians should consult local guidelines for administration in case of limited supplies.

Vaccines are available for influenza and SARS-CoV-2, which, although contributing significantly to the overall burden of respiratory disease, account for only a small proportion of bronchiolitis cases. Nonetheless, the American Academy of Pediatrics and other healthcare organizations recommend age-appropriate vaccination for all infants and children to prevent these infections. For infants too young for vaccination, vaccinating household members and close contacts is essential to minimize the risk of disease transmission.

Differential Diagnosis

The differential diagnoses of bronchiolitis include:

• Gastroesophageal reflux
• Aspiration pneumonia
• Foreign body aspiration into the lower airway
• Congenital malformations, such as vascular rings or slings
• Acute exacerbation of asthma
• Acute anaphylaxis

Prognosis

The prognosis of bronchiolitis is generally favorable, with most infants recovering within 5 to 7 days. Although some studies suggest an increased risk of asthma following bronchiolitis, only a small percentage of affected children develop asthma. A history of recurrent wheezing and a positive family history of asthma, allergies, or atopic dermatitis may increase the likelihood of asthma development in these patients in the future.[18]

Complications

Complications from bronchiolitis are uncommon but can be severe, particularly in infants who are premature or have underlying pulmonary, cardiac, or immunocompromised conditions. Even healthy infants may experience acute or chronic complications, although most recover without incident.[19][20][21][22][23]

Acute complications of bronchiolitis include:

• Aspiration
• Respiratory failure
• Apnea
• Secondary bacterial infections
• Death

Chronic complications of bronchiolitis include:

• Recurrent episodes of wheezing
• Bronchiolitis obliterans 

Deterrence and Patient Education

Healthcare providers should continue encouraging age-appropriate vaccinations against influenza, SARS-CoV-2, and RSV. For RSV prevention, this includes vaccinating the pregnant parent and administering nirsevimab, a monoclonal antibody given once during the infant's first RSV season, to reduce the risk of the most common cause of bronchiolitis.

For infants too young to be vaccinated, it is crucial to ensure that close contacts are up to date on vaccinations, particularly for RSV, influenza, and SARS-CoV-2. Parents should be advised to follow good infection control practices, such as frequent handwashing, avoiding exposure to individuals with respiratory symptoms, and maintaining a smoke-free and pollutant-free home environment. Breastfeeding should also be encouraged, as it offers additional protection to the infant against pathogens encountered by the birth parent.

Pearls and Other Issues

Key facts to keep in mind about bronchiolitis include:

• Bronchiolitis is a viral lower respiratory tract infection that causes inflammation and obstruction of the small airways.

• The condition primarily affects infants and young children aged 2 or younger, with peak incidence occurring between 2 and 6 months.

• RSV is the most common cause of bronchiolitis, although other common pathogens, such as human metapneumovirus, parainfluenza, rhinovirus, adenovirus, and influenza or SARS-CoV-2, are also implicated.

• Initial symptoms include upper respiratory symptoms such as nasal congestion, rhinorrhea, and cough. Symptoms can progress to tachypnea, wheezing, intercostal retractions, nasal flaring, and hypoxemia. 

• Severe symptoms include poor feeding, lethargy, cyanosis, and signs of respiratory distress or failure (such as grunting and belly breathing).

• Diagnosis is based on the patient's history and physical examination.

• Viral testing should be considered for hospitalized infants, especially for isolation and infection control.

• The mainstay of treatment includes supportive care such as hydration, nasal suctioning, and oxygen therapy for hypoxemia.

• Routine use of glucocorticoids or antibiotics is not recommended.

• Antivirals, such as oseltamivir for influenza or nirmatrelvir-ritonavir for SARS-COV-2, may be used when indicated.

• Pregnant individuals are advised to receive the RSV vaccine. 

• Nirsevimab monoclonal antibody should be administered during the infant's first respiratory season if the birth parent has not been vaccinated.

• General measures, such as hand hygiene, avoiding exposure to respiratory infections, and maintaining a smoke-free environment, should be practiced.

• Premature infants are at a higher risk of severe disease.

• Infants with cardiac, pulmonary, or immunodeficiency disorders are more likely to experience complications.

• Although an x-ray is not routinely indicated, it may reveal hyperinflation and peribronchial thickening if obtained.

Enhancing Healthcare Team Outcomes

The management of bronchiolitis is best achieved through an interprofessional team approach, which involves emergency department physicians, nurse practitioners, pediatric nurses, infectious disease consultants, and primary care providers. Most children recover with supportive care alone.

Healthcare providers should encourage breastfeeding, as it has been shown to reduce the risk of respiratory infections in children. As the virus is transmitted via respiratory droplets, implementing contact isolation precautions—such as proper handwashing, hand sanitizing, and wearing gowns, gloves, and masks—is essential to preventing infection among hospitalized infants. The use of gloves and gowns is particularly effective in the hospital setting for reducing transmission when entering and exiting the rooms of infected patients. Most children improve spontaneously within a few days, with only a few cases requiring hospital admission.[24][25]

Discussions about preventing infectious illnesses should begin at birth or, ideally, during prenatal visits with a healthcare provider. Prevention strategies should include smoking cessation, particularly for individuals in direct contact with the infant, and maintaining a clean, smoke-free environment. Vaccinating all children older than 6 months against influenza and SARS-CoV-2 is a critical preventive measure. For infants aged 6 months or younger, it is essential that family members and caregivers receive vaccinations for influenza and SARS-CoV-2 to provide indirect protection to the infant.

Interdisciplinary healthcare team members can reinforce preventive measures by counseling the family in various settings, including the office, emergency department, or hospital. Providing written materials in the family’s native language and ensuring consistent communication across all contact points within the medical team are essential for achieving positive outcomes and enhancing family satisfaction.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simões EAF, Campbell H, Pariente AB, Bardach D, Bassat Q, Casalegno JS, Chakhunashvili G, Crawford N, Danilenko D, Do LAH, Echavarria M, Gentile A, Gordon A, Heikkinen T, Huang QS, Jullien S, Krishnan A, Lopez EL, Markić J, Mira-Iglesias A, Moore HC, Moyes J, Mwananyanda L, Nokes DJ, Noordeen F, Obodai E, Palani N, Romero C, Salimi V, Satav A, Seo E, Shchomak Z, Singleton R, Stolyarov K, Stoszek SK, von Gottberg A, Wurzel D, Yoshida LM, Yung CF, Zar HJ, Respiratory Virus Global Epidemiology Network. Nair H., RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022 May 28;399(10340):2047-2064. [PMC free article: PMC7613574] [PubMed: 35598608]

2.

Remien KA, Amarin JZ, Horvat CM, Nofziger RA, Page-Goertz CK, Besunder JB, Potts BK, Forbes ML, Halasa N, Pelletier JH. Admissions for Bronchiolitis at Children's Hospitals Before and During the COVID-19 Pandemic. JAMA Netw Open. 2023 Oct 02;6(10):e2339884. [PMC free article: PMC10603547] [PubMed: 37883085]

3.

Dalziel SR, Haskell L, O'Brien S, Borland ML, Plint AC, Babl FE, Oakley E. Bronchiolitis. Lancet. 2022 Jul 30;400(10349):392-406. [PubMed: 35785792]

4.

Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. Lancet. 2017 Jan 14;389(10065):211-224. [PMC free article: PMC6765220] [PubMed: 27549684]

5.

Yusuf S, Piedimonte G, Auais A, Demmler G, Krishnan S, Van Caeseele P, Singleton R, Broor S, Parveen S, Avendano L, Parra J, Chavez-Bueno S, Murguía De Sierra T, Simoes EA, Shaha S, Welliver R. The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Epidemiol Infect. 2007 Oct;135(7):1077-90. [PMC free article: PMC2870672] [PubMed: 17346359]

6.

Teoh Z, Conrey S, McNeal M, Burrell A, Burke RM, Mattison CP, McMorrow M, Thornburg N, Payne DC, Morrow AL, Staat MA. Factors Associated With Prolonged Respiratory Virus Detection From Polymerase Chain Reaction of Nasal Specimens Collected Longitudinally in Healthy Children in a US Birth Cohort. J Pediatric Infect Dis Soc. 2024 Mar 19;13(3):189-195. [PMC free article: PMC11520743] [PubMed: 38366142]

7.

Checchia PA, Paes B, Bont L, Manzoni P, Simões EA, Fauroux B, Figueras-Aloy J, Carbonell-Estrany X. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease. Infect Dis Ther. 2017 Mar;6(1):37-56. [PMC free article: PMC5336417] [PubMed: 28070870]

8.

Nenna R, Cutrera R, Frassanito A, Alessandroni C, Nicolai A, Cangiano G, Petrarca L, Arima S, Caggiano S, Ullmann N, Papoff P, Bonci E, Moretti C, Midulla F. Modifiable risk factors associated with bronchiolitis. Ther Adv Respir Dis. 2017 Oct;11(10):393-401. [PMC free article: PMC5933664] [PubMed: 28812472]

9.

Riikonen R, Korppi M, Törmänen S, Koponen P, Nuolivirta K, Helminen M, He Q, Lauhkonen E. Risk factors for irreversible airway obstruction after infant bronchiolitis. Respir Med. 2021 Oct;187:106545. [PubMed: 34332337]

10.

Choudhuri JA, Ogden LG, Ruttenber AJ, Thomas DS, Todd JK, Simoes EA. Effect of altitude on hospitalizations for respiratory syncytial virus infection. Pediatrics. 2006 Feb;117(2):349-56. [PubMed: 16452353]

11.

Nicholson EG, Schlegel C, Garofalo RP, Mehta R, Scheffler M, Mei M, Piedra PA. Robust Cytokine and Chemokine Response in Nasopharyngeal Secretions: Association With Decreased Severity in Children With Physician Diagnosed Bronchiolitis. J Infect Dis. 2016 Aug 15;214(4):649-55. [PMC free article: PMC4957440] [PubMed: 27190183]

12.

Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007 Jan;20(1):108-19. [PubMed: 17143259]

13.

Sebina I, Phipps S. The Contribution of Neutrophils to the Pathogenesis of RSV Bronchiolitis. Viruses. 2020 Jul 27;12(8) [PMC free article: PMC7472258] [PubMed: 32726921]

14.

Johansson C, Kirsebom FCM. Neutrophils in respiratory viral infections. Mucosal Immunol. 2021 Jul;14(4):815-827. [PMC free article: PMC7985581] [PubMed: 33758367]

15.

Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014 Dec;35(12):519-30. [PMC free article: PMC5029757] [PubMed: 25452661]

16.

Horvat CM, Pelletier J. A Trial of Albuterol Should Still Be Considered for Children With Severe Bronchiolitis. JAMA Pediatr. 2021 Nov 01;175(11):1182-1183. [PMC free article: PMC8883329] [PubMed: 34370000]

17.

Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sánchez PJ, Kotton CN, Mahon BE, Meyer S, Long SS, McMorrow ML. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 25;72(34):920-925. [PMC free article: PMC10468217] [PubMed: 37616235]

18.

Törmänen S, Lauhkonen E, Riikonen R, Koponen P, Huhtala H, Helminen M, Korppi M, Nuolivirta K. Risk factors for asthma after infant bronchiolitis. Allergy. 2018 Apr;73(4):916-922. [PubMed: 29105099]

19.

Hon KL, Leung AKC, Wong AHC, Dudi A, Leung KKY. Respiratory Syncytial Virus is the Most Common Causative Agent of Viral Bronchiolitis in Young Children: An Updated Review. Curr Pediatr Rev. 2023;19(2):139-149. [PubMed: 35950255]

20.

Ghazaly MMH, Abu Faddan NH, Raafat DM, Mohammed NA, Nadel S. Acute viral bronchiolitis as a cause of pediatric acute respiratory distress syndrome. Eur J Pediatr. 2021 Apr;180(4):1229-1234. [PMC free article: PMC7648537] [PubMed: 33161501]

21.

Abreo A, Wu P, Donovan BM, Ding T, Gebretsadik T, Huang X, Stone CA, Turi KN, Hartert TV. Infant Respiratory Syncytial Virus Bronchiolitis and Subsequent Risk of Pneumonia, Otitis Media, and Antibiotic Utilization. Clin Infect Dis. 2020 Jun 24;71(1):211-214. [PMC free article: PMC7312311] [PubMed: 31630167]

22.

Jerkic SP, Brinkmann F, Calder A, Casey A, Dishop M, Griese M, Kurland G, Niemitz M, Nyilas S, Schramm D, Schubert R, Tamm M, Zielen S, Rosewich M. Postinfectious Bronchiolitis Obliterans in Children: Diagnostic Workup and Therapeutic Options: A Workshop Report. Can Respir J. 2020;2020:5852827. [PMC free article: PMC7013295] [PubMed: 32076469]

23.

Reichert H, Suh M, Jiang X, Movva N, Bylsma LC, Fryzek JP, Nelson CB. Mortality Associated With Respiratory Syncytial Virus, Bronchiolitis, and Influenza Among Infants in the United States: A Birth Cohort Study From 1999 to 2018. J Infect Dis. 2022 Aug 15;226(Suppl 2):S246-S254. [PMC free article: PMC9377030] [PubMed: 35968877]

24.

Luo G, Stone BL, Nkoy FL, He S, Johnson MD. Predicting Appropriate Hospital Admission of Emergency Department Patients with Bronchiolitis: Secondary Analysis. JMIR Med Inform. 2019 Jan 22;7(1):e12591. [PMC free article: PMC6362392] [PubMed: 30668518]

25.

Slain KN, Rotta AT, Martinez-Schlurmann N, Stormorken AG, Shein SL. Outcomes of Children With Critical Bronchiolitis Meeting at Risk for Pediatric Acute Respiratory Distress Syndrome Criteria. Pediatr Crit Care Med. 2019 Feb;20(2):e70-e76. [PubMed: 30461577]

Disclosure: Evelyn Erickson declares no relevant financial relationships with ineligible companies.

Disclosure: Rupal Bhakta declares no relevant financial relationships with ineligible companies.

Disclosure: Debbie Tristram declares no relevant financial relationships with ineligible companies.

Disclosure: Magda Mendez declares no relevant financial relationships with ineligible companies.